RT Journal Article
SR Electronic
T1 Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00684-2021
DO 10.1183/23120541.00684-2021
A1 Emily Pei-Ying Lin
A1 Li-Ching Huang
A1 Jennifer Whisenant
A1 Sally York
A1 Travis Osterman
A1 Jennifer Lewis
A1 Wade Iams
A1 Emily Skotte
A1 Amanda Cass
A1 Chih-Yuan Hsu
A1 Yu Shyr
A1 Leora Horn
YR 2022
UL http://openres.ersjournals.com/content/early/2022/06/23/23120541.00684-2021.abstract
AB Background Whether influenza vaccination (FV) is associated with the severity of immune-related adverse events (IRAE) in patients with advanced thoracic cancer on immune checkpoint inhibitors (ICI) is not fully understood.Methods Patients enrolled in this retrospective cohort study were identified from the Vanderbilt BioVU database and their medical records were reviewed. Patients with advanced thoracic cancer who received FV within 3 months prior to or during their ICI treatment period were enrolled in the FV-positive cohort and those who did not were enrolled in the FV-negative cohort. The primary objective was to detect whether FV is associated with decreased IRAE severity. The secondary objectives were to evaluate whether FV is associated with a decreased risk for grade 3–5 IRAE and better survival times. Multivariable ordinal logistic regression was used for primary analysis.Results A total of 142 and 105 patients were enrolled in the FV-positive and FV-negative cohorts, respectively. There was no statistically significant difference in patient demographics or cumulative incidences of IRAE between the two cohorts. In the primary analysis, FV was inversely associated with the severity of IRAE (odds ratio=0.63; p=0.046). In the secondary analysis, FV was associated with a decreased risk for grade 3–5 IRAE (odds ratio=0.42; p=0.005). Multivariable Cox regression showed that FV was not associated with survival times.Conclusions Our study showed that FV does not increase toxicity for patients with advanced thoracic cancer on ICI and is associated with a decreased risk for grade 3–5 IRAE. No statistically significant survival differences were found between patients with and without FV.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Emily Pei-Ying Lin has received support for the present manuscript from Ministry of Science and Technology Taiwan [MOST107-2314-B-002-231, MOST108-2314-B-030-014, MOST109-2314-B-038-150, MOST108-2314-B-002-197-MY2], and National Health Research Institute Taiwan [NHRI-EX109-10937BC].Conflict of interest: Travis Osterman has received grants or contracts from Microsoft, outside the submitted work. Consulting fees received from AstraZeneca, outside the submitted work. Other financial or non-financial interests; GE Healthcare – Collaboration.Conflict of interest: Wade Iams has received grants or contracts from National Cancer Institute (NCI) Vanderbilt Clinical Oncology Research Career Development Award (VCORCDP) 2K12CA090625-17, American Society of Clinical Oncology / Conquer Cancer Foundation Young Investigator Award, and National Comprehensive Cancer Network Young Investigator Award, outside the submitted work. Consulting fees received from OncLive, Clinical Care Options, Chardan, Outcomes Insights, Cello Health and Curio Science, outside the submitted work. Participation on a Advisory Board for Genentech, Jazz Pharma, G1 Therapeutics and Mirati, outside the submitted work.Conflict of interest: Amanda Cass has received payment or honoraria for speakers bureaus from Jazz, outside the submitted work. Participation on a advisory board for Roche-Genentech and Novartis, outside the submitted work.Conflict of interest: Yu Shyr has received support for the present manuscript from National Institutes of Health [P30CA068485, U24CA163056, U24CA213274, P50CA236733, P50CA098131, U54CA163072].Conflict of interest: Leora Horn has received grants or contracts from Xcovery and Bristol Myers Squibb, outside the submitted work. Consulting fees received from AstraZeneca, Xcovery and Amgen, outside the submitted work. Participation on a advisory board for Roche-Genentech, Bristol Myers Squibb, Merck, Incyte and Tesaro, outside the submitted work. Other financial or non-financial interests; AstraZeneca - Employment (9/20).Conflict of interest: The remaining authors have nothing to disclose.